Date: 2015-06-17
Type of information: Licensing agreement
Compound: Rapivab® (peramivir injection)
Company: CSL (Australia) BioCryst Pharmaceuticals (USA - NC)
Therapeutic area: Infectious diseases
Type agreement: licensing
Action mechanism: antiviral agent/ neuraminidase inhibitor. Peramivir is a novel investigational intravenous neuraminidase inhibitor that exhibits potent antiviral activity against influenza A and B viruses. Peramivir consists of a cyclopentane backbone with a positively charged guanidinyl group and lipophilic side chains. In January 2010, Shionogi & Co., Ltd. launched intravenous peramivir in Japan under the name Rapiacta® and in August 2010, Green Cross Corporation announced that it had received marketing and manufacturing authorization for i.v. peramivir in Korea under the name PeramiFlu®. It is estimated that more than one million patients have received peramivir treatment to date. Peramivir has been approved by FDA in December 2014.
Disease: influenza
Details: * On June 17, 2015, BioCryst Pharmaceuticals announced that it has licensed Rapivab® (peramivir injection) for the treatment of influenza to CSL. Rapivab® is an intravenous (I.V.) treatment indicated in the U.S. for acute uncomplicated influenza in adults 18 years and older. It is also currently licensed for use in Japan and Korea, and is the first and only approved intravenous influenza treatment in the world. It will be commercialized by CSL\'s subsidiary, bioCSL, which specializes in influenza prevention through the supply of seasonal and pandemic influenza vaccine to global markets. Under the terms of the agreement, bioCSL obtains worldwide rights to commercialize Rapivab®, with the exception of Japan, Korea, Taiwan and Israel. BioCryst retains all rights to pursue pandemic stockpiling orders for Rapivab® from the U.S. government, while bioCSL is responsible for government stockpiling outside the U.S.
Financial terms: Under the terms of the agreement, BioCryst will receive an upfront payment of $33.7 million from bioCSL, and may receive up to $12.0 million in additional payments related to the successful achievement of certain regulatory milestones. BioCryst will receive tiered royalties that are contingent upon certain net sales thresholds in the U.S. and the rest of the world, as well as a percentage of proceeds from government stockpiling purchases outside the U.S. In addition, bioCSL will purchase existing and in-process inventory of RAPIVAB for treatment of influenza patients in upcoming flu seasons.
Latest news:
